# Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

> **NCT00684177** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 508 (actual)

## Conditions studied

- Skin Infections, Bacterial

## Interventions

- **DRUG:** Retapamulin Ointment, 1%
- **DRUG:** Placebo ointment

## Key facts

- **NCT ID:** NCT00684177
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684177, "Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00684177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*